Literature DB >> 8879231

Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation.

F Grimminger1, K Hattar, C Papavassilis, B Temmesfeld, E Csernok, W L Gross, W Seeger, U Sibelius.   

Abstract

Among the anti-neutrophil cytoplasmic antibodies (ANCA), those targeting proteinase 3 (PR3) have a high specificity for Wegener's granulomatosis (WG). It is known that a preceding priming of neutrophils with cytokines is a prerequisite for membrane surface expression of PR3, which is then accessible to autoantibody binding. Employing a monoclonal antibody directed against human PR3 and ANCA-positive serum from WG patients with specificity for PR3, we now investigated the role of free arachidonic acid (AA) in autoantibody-related human neutrophil activation. Priming of neutrophils with tumor necrosis factor (TNF-alpha) for 15 min or exposure to anti-PR3 antibodies or incubation with free AA (10 microM) as sole events did not provoke superoxide generation, elastase secretion or generation of 5-lipoxygenase products of AA. Similarly, the combination of TNF-alpha-priming and AA incubation was ineffective. When TNF-alpha-primed neutrophils were stimulated by anti-PR3 antibodies, superoxide and elastase secretion was provoked in the absence of lipid mediator generation. However, when free AA was additionally provided, a strong activation of the 5-lipoxygenase pathway was demasked, with the appearance of excessive quantities of leukotriene (LT)B4, LTA4, and 5-hydroxyeicosatetraenoic acid. Moreover, superoxide and elastase secretion were markedly amplified, and studies with 5-lipoxygenase inhibitors and a LTB4-antagonist demonstrated this was due to an LTB4-related autocrine loop of cell activation. In contrast, the increased synthesis of platelet-activating factor in response to TNF-alpha-priming and anti-PR3 stimulation did not contribute to the amplification loop of neutrophil activation under the given conditions. We conclude that anti-PR3 antibodies are potent inductors of the 5-lipoxygenase pathway in primed human neutrophils, and extracellular free AA, as provided at an inflammatory focus, synergizes with the autoantibodies to evoke full-blown lipid mediator generation, granule secretion and respiratory burst. Such events may be enrolled in the pathogenesis of focal necrotizing vascular injury in Wegener's granulomatosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879231      PMCID: PMC2192817          DOI: 10.1084/jem.184.4.1567

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  Permeability and vasomotor response of cerebral vessels during exposure to arachidonic acid.

Authors:  A Unterberg; M Wahl; F Hammersen; A Baethmann
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

2.  Lipid transfer between endothelial and smooth muscle cells in coculture.

Authors:  L L Stoll; A A Spector
Journal:  J Cell Physiol       Date:  1987-10       Impact factor: 6.384

3.  Endothelial cell leukotriene C4 synthesis results from intercellular transfer of leukotriene A4 synthesized by polymorphonuclear leukocytes.

Authors:  S J Feinmark; P J Cannon
Journal:  J Biol Chem       Date:  1986-12-15       Impact factor: 5.157

4.  Botulinum C2 toxin ADP-ribosylates actin.

Authors:  K Aktories; M Bärmann; I Ohishi; S Tsuyama; K H Jakobs; E Habermann
Journal:  Nature       Date:  1986 Jul 24-30       Impact factor: 49.962

5.  Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

Authors:  F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

6.  Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis.

Authors:  S Hammarström; M Hamberg; B Samuelsson; E A Duell; M Stawiski; J J Voorhees
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

7.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

Authors:  R J Falk; J C Jennette
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

8.  Human endothelial cells stimulate leukotriene synthesis and convert granulocyte released leukotriene A4 into leukotrienes B4, C4, D4 and E4.

Authors:  H E Claesson; J Haeggström
Journal:  Eur J Biochem       Date:  1988-04-05

9.  1-ether-linked phosphoglycerides. Major endogenous sources of arachidonate in the human neutrophil.

Authors:  F H Chilton; T R Connell
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

10.  A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells.

Authors:  R Kain; K Matsui; M Exner; S Binder; G Schaffner; E M Sommer; D Kerjaschki
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  9 in total

1.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

Authors:  Hong Xiao; Peter Heeringa; Peiqi Hu; Zhi Liu; Minglang Zhao; Yasuaki Aratani; Nobuyo Maeda; Ronald J Falk; J Charles Jennette
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Early vasculitis in the mercuric chloride induced Brown Norway rat model is neutrophil independent.

Authors:  F E Harris; D R Turner; D B Oliveira
Journal:  Int J Exp Pathol       Date:  1999-06       Impact factor: 1.925

Review 3.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Antibodies to proteinase 3 prime human oral, lung, and kidney epithelial cells to secrete proinflammatory cytokines upon stimulation with agonists to various Toll-like receptors, NOD1, and NOD2.

Authors:  Akiko Uehara; Yasuhiko Hirabayashi; Haruhiko Takada
Journal:  Clin Vaccine Immunol       Date:  2008-05-21

5.  Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response.

Authors:  U Sibelius; K Hattar; A Schenkel; T Noll; E Csernok; W L Gross; W J Mayet; H M Piper; W Seeger; F Grimminger
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

6.  PR3-ANCA in Wegener's granulomatosis prime human mononuclear cells for enhanced activation via TLRs and NOD1/2.

Authors:  Akiko Uehara; Tadasu Sato; Atsushi Iwashiro; Sou Yokota
Journal:  Diagn Pathol       Date:  2009-07-14       Impact factor: 2.644

7.  Distinct eicosanoid profile in exhaled breath condensates from granulomatosis with polyangiitis (Wegener's) patients.

Authors:  Wojciech Szczeklik; Marek Sanak; Barbara Sokołowska; Bogdan Jakieła; Jan Sznajd; Anna Gielicz; Marek Kaszuba; Agata Sawina; Jacek Musiał
Journal:  Clin Rheumatol       Date:  2013-06-02       Impact factor: 2.980

8.  The Diagnostic Value of Alpha-1-Antitrypsin Phenotype in Patients with Granulomatosis with Polyangiitis.

Authors:  M Y Pervakova; V L Emanuel; O N Titova; S V Lapin; V I Mazurov; I B Belyaeva; A L Chudinov; T V Blinova; E A Surkova
Journal:  Int J Rheumatol       Date:  2016-04-10

9.  Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation.

Authors:  Konstantin Mayer; Christine Fegbeutel; Katja Hattar; Ulf Sibelius; Hans-Joachim Krämer; Kai-Uwe Heuer; Bettina Temmesfeld-Wollbrück; Stephanie Gokorsch; Friedrich Grimminger; Werner Seeger
Journal:  Intensive Care Med       Date:  2003-07-25       Impact factor: 17.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.